Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

NCT00874432
View directory record Official record
Conditions
Cardiovascular Disease, Chronic Kidney Disease
Interventions
angiotensin converting enzyme inhibitor, lisinopril
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Research to Policy Collaboration Model

NCT03671434
View directory record Official record
Conditions
Legislation, Policy, Child Abuse, Family and Household
Interventions
Research-to-Policy Collaboration, Light Touch Policy Training
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

Synchronized Transcranial Magnetic Stimulation for PTSD

NCT02981381
View directory record Official record
Conditions
PTSD, Depression
Interventions
NEST-1, SHAM, NEST-2
Device
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Providence, Rhode Island • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 25, 2026, 7:28 AM EDT
Terminated Not applicable Interventional

Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty

NCT04191031
View directory record Official record
Conditions
Post-Operative Pain Management
Interventions
ioveraº, ioveraº sham
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
22 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Fremont, California • Pasadena, California • Tamarac, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 25, 2026, 7:28 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

NCT04919109
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CodaVax-RSV, Normal Saline
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
6 Months to 5 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474
View directory record Official record
Conditions
Wounds
Interventions
Placebo gel, GLYC-101 gel (1.0 %)
Drug
Lead sponsor
TR Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 7:28 AM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen, Sham Comparator
Drug · Other
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2

NCT06068946
View directory record Official record
Conditions
Weight Loss
Interventions
VK2735, Placebo
Biological
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 25, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

NCT04869943
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 25, 2026, 7:28 AM EDT
Not yet recruiting Not applicable Interventional

Reduction of Anxiety Through Dual Treatment: Digital CBT & NBHWC Coaching

NCT07140497
View directory record Official record
Conditions
Hearing Disability, Anxiety, Mobility Disability
Interventions
Sham Digital Program - General health education and interactive quizzes unrelated to anxiety or CBT., Toivoa-001 - A digital Cognitive Behavioral Therapy program combined with NBHWC-certified coaching.
Device
Lead sponsor
Toivoa Inc
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Dover, Delaware • East Orange, New Jersey • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Effect of PP-01 on Cannabis Withdrawal Syndrome

NCT05494437
View directory record Official record
Conditions
Cannabis Withdrawal
Interventions
PP-01 High Dose, PP-01 Low Dose, Placebo, Nabilone, Gabapentin
Combination Product · Drug
Lead sponsor
PleoPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Glendale, California • Lemon Grove, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 25, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls

NCT04498442
View directory record Official record
Conditions
Covid19, Stress, Anxiety Depression
Interventions
Simha Kriya, Reading a Book
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
8,519 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 25, 2026, 7:28 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2

NCT07321327
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit for Caregivers, Positive Behavioral Management Toolkit for Teachers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

NCT01103414
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mitoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

NCT00345384
View directory record Official record
Conditions
Post-operative Pain, Respiratory Depression
Interventions
Dexmedetomidine, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Protandim Supplementation on Oxidative Damage and Athletic Performance

NCT02172625
View directory record Official record
Conditions
Oxidative Stress
Interventions
Protandim Dietary Supplement, Placebo Group
Dietary Supplement · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

NCT00700817
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 25, 2026, 7:28 AM EDT
Recruiting Not applicable Interventional

The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV

NCT07226128
View directory record Official record
Conditions
HIV, Depression in Adults, Insulin Resistance, Cognitive Behavior Therapy
Interventions
Internet cognitive behavioral therapy (iCBT-D), Active Control (AC)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
View directory record Official record
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 25, 2026, 7:28 AM EDT